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Summary 
The leukocyte-restricted 92 (CD18) integrlns mediate 
cell adhesion in a variety of events essential for normal 
immune function. Despite extensive research in this 
field, only three members of this lntegrin subfamily 
have been descrfbed: CDllaKD18 (LFA-l), CDllbl 
CD18 (Mac-l), and CDllclCD18 (pl50,95). We have 
identified a cDNA encoding a fourth a chain, ad, that 
associates with CD19 The ad subunit is more closely 
related to CDllb and CDllc than to CDlla. This in- 
tegrfn is expressed at moderate levels on myelo- 
monocytlc cell lines and subsets of peripheral blood 
leukocytes, and more strongly on tissue-compart- 
mentalized cells such as foam cells, specialized mac- 
rophages found In aortlc fatty streaks that may develop 
Into atherosclerotic lesions. The ad/CD18 molecule 
exhibits preferential recognition of ICAM- over 
ICAM-1. 
Introduction 
The integrins are a family of heterodimeric membrane- 
bound glycoproteins that mediate homotypic and hetero- 
typic cell-cell adhesion in a broad range of biological con- 
texts (Hynes, 1992; Larson and Springer, 1990). A 
subfamily of integrins expressed in leukocytes is defined 
by a common beta chain, 82 (CDl8), that pairs with a 
distinct subgroup of a chains (Hynes, 1987). These a 
chains contain a region of approximately 200 aa residues, 
designated the I (inserted) or A domain, that shares struc- 
tural homology to ligand-binding domains in Von Wille- 
brand factor and other proteins (Larson and Springer, 
1990; Michishita et al., 1993; Lee et al., 1995) and has 
recently been implicated in ligand recognition (Landis et 
al., 1993; Diamond et al., 1993; Randi and Hogg, 1994; 
Zhou et al., 1994). The leukointegrins are critical to im- 
mune function: absence of CD18 cell surface expression 
in patients with leukocyte adhesion deficiency (LAD) re- 
sults in impairment of a variety of immune functions, in- 
cluding neutrophil transendothelial migration, macrophage 
oxidative burst and phagocytosis, and lymphocyte prolifer- 
ation (Springer et al., 1984; Anderson and Springer, 1987). 
To date, the leukointegrin subfamily includes CD1 1 a/ 
CD18, CD11 blCDl8, and CDllcED18, also known as 
LFA-1, Mac-l, and p150,95, respectively (Kishimoto et al., 
1987; Corbi et al., 1987, 1988; Larson et al., 1989). LFA-1 
cell surface expression is constitutive on a broad range 
of leukocytes, while expression of Mac-l and p150,95 is 
more restricted and inducible by inflammatory mediators 
(Larson and Springer, 1990). LFA-1 and Mac-l mediate 
cell-cell contact by interacting with the intercellular adhe- 
sion molecules (ICAMs), immunoglobulin superfamily 
members (Hynes, 1992; Larson and Springer, 1990). 
Whereas both LFA-1 and Mac-l bind to ICAM-1, only 
LFA-1 has been demonstrated to bind to ICAM3. ICAM- 
is highly expressed on resting lymphocytes and its linkage 
to intracellular signal transduction pathways contributes 
to lymphocyte activation (Vives, 1994). Here, we report 
the identification of a novel fourth leukointegrin a chain, 
ad, that contains an I or A domain and is most homologous 
to Mac-l and p150,95. The ad protein is expressed on 
myelomonocytic cell lines in a pattern distinct from that 
of CD1 1 band CD1 lc. This molecule is expressed predom- 
inantly in splenic red pulp on macrophages and granulo- 
cytic cells in an overlapping but nonidentical pattern with 
the other leukointegrin a chains. The protein can be de- 
tected at low levels relative to CD1 la and CD1 1 bon sub- 
sets of peripheral blood cells. In addition, it is present on 
lipid laden macrophages in aortic fatty streaks. This a 
chain forms a heterodimer with 82 that binds ICAM- but 
not ICAM- when expressed in Chinese hamster ovary 
(CHO) cells. 
Results and Discussion 
For analyses of 82 integrin function in the dog, Danilenko 
et al. (1992) generated a panel of monoclonal antibodies 
(MAbs) against canine CD18 complexes. Interestingly, 
one of these canine-specific antibodies recognized a 
CD18-associated protein with histologic distribution and 
apparent molecular weight distinct from that of the known 
leukointegrins (Danilenko et al., 1995). The expression 
pattern of this molecule was restricted mainly to tissues 
and differed from the distribution of CD1 1 b and CD1 1 c. 
Amino-terminal sequence derived from this a chain indi- 
cated leukointegrin homology; however, this protein could 
not be defined as the distinct product of a novel gene 
since no sequence information regarding canine CD1 1 a, 
CD1 1 b, or CD1 lc was available for comparison. A priori, 
these findings might also be explained by cell-type specific 
mRNA splicing, posttranslational modification, or unex- 
pected pairing of CD18 with known integrin a chains from 
other subfamilies. 
We presumed that DNA fragments amplified from ca- 
nine cDNA could be used in cross-species hybridizations 
to identify a human homolog, thus permitting direct com- 
parisons with known a subunits. We obtained peptide se- 
quences for polymerase chain reaction (PCR) primer de- 
sign from fragmentation of the ad protein isolated from 
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canine spleen. Degenerate oligonucleotides based on 2 
of 9 peptides sequenced were used as primers in a PCR 
with canine splenic cDNA to amplify a 1 kb DNA fragment. 
This fragment was used as a probe to identify a homolo- 
gous clone (19A2) in a human spleen cDNA library under 
stringent hybridization conditions. Although no exact 
matches with any sequence in the National Center for Bio- 
technology Information databases were found, sequence 
homologies to the known leukointegrin a chains sug- 
gested that the protein encoded by clone 19A2 belonged 
to this integrin subfamily. This clone appears to share se- 
quence homology with a partial genomic clone identified 
independently (D. Wong, personal communication). We 
have designated this previously unidentified a chain ad. 
As shown in Figure 1, clone 19A2 encompasses the 
entire coding region for the mature protein, including 13 
residues of leader sequence. Two additional clones have 
been isolated and used to confirm this sequence and to 
indicate that a methionine precedes the 19A2 leader se- 
quence. The putative amino acid sequence shares greater 
identity to CD1 1 b (60%) and CD1 lc (66%) than to CD1 1 a 
(36%). The molecular mass of the mature core protein 
is predicted to be 125 kDa with an extracellular domain 
encompassing 1064 residues followed by a hydrophobic 
23residue potential transmembrane domain and a 36- 
residue cytoplasmic tail. There are eleven potential N-linked 
glycosylation sites. The seven homologous internal re- 
peats observed in CDlla, CD11 b, and CD1 ic are also 
conserved in ad. 
Also present in ad is a 204residue segment homolo- 
gous to the I or A domain recently implicated in.ligand 
recognition (Landis et al., 1993; Diamond et al., 1993; 
Randi and Hogg, 1994; Edwards et al., 1995). The I domain 
Figure 1. Amino Acid Sequence of the ad Subunit 
Leader sequence is denoted by lowercase letters. Additional cDNA 
clones have confirmed the single methionine preceding the leader 
sequence from clone 19A2. Homologous internal repeats are labeled 
with roman numerals at their amino-terminal ends. The I domain is 
underlined. Putative cation binding sites are indicated in bold letters; 
the MIDAS motif is included in the first cation binding site. Potential 
N-linked glycosytation sites are underlined. The transmembrane do- 
main, denoted by carets, immediately precedes the cytoplasmic dc- 
main. The cytoplasmic KLGFFKR motif is in italics. The nucleotide 
sequence of clone 19A2 can be obtained from the Genbank database 
(accession number U37026). 
ad 
205 kD - 
116kD- 
CD18 
Figure 2. ad Forms a Heterodimer with 62. 
CD16 
Heterodimeric complexes immunoprecipitated 
from lysates of biotinylated ad/CD16 CHO 
transfectants with either ad- or CDWspecific 
MAb were visualized with peroxidase- 
conjugated strepavidin. Lane 1, ad/CD16 CHO 
plus mouse IgG; lane 2, ad/CD16 CHO plus 
TS1118; lane 3, ad/CD16 CHO plus 169A. Cell 
surface expression of CD16 required cotrans- 
fection of the ad cDNA: transient transfections 
of the 6 chain construct alone did not result in 
detectable CD16 expression by flow cytometry 
and in immunoprecipitation experiments (data 
not shown). 
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amino acid sequence is 36%, 62%, and 57% identical to 
the same regions in CD1 la, CD1 1 b, and CD1 lc, respec- 
tively. ad also contains identical residues defined in the 
I domain of CD1 1 b as a metal iondependent adhesion 
site (MIDAS) necessary for ligand binding (Michishita et 
al., 1993, Lee et al., 1995) as well as three additional 
cation binding sites conserved in leukointegrin a subunits. 
There is similarity between the peptide sequences from 
CD11 b, which have been demonstrated to interact with 
complement component iC3b (Ueda, et al., 1994) and the 
homologous region in ad. The moderate level of sequence 
conservation in these regions suggests that while ad may 
share ligands with the known leukointegrins, it may also 
recognize distinct cell surface or extracellular matrix pro- 
teins. 
The cytoplasmic domains of integrin a subunits are im- 
plicated in integrin activation. These domains are typically 
unrelated to one another, but conserved across species. 
The putative cytoplasmic sequence of ad differs markedly 
from that of CDlla, CDllb, andCDllc(lO%, 16%, and 
16% identity, respectively), except for the membrane prox- 
imal KXGFFKR motif, conserved among all a integrins, 
that is involved in affinity regulation from the cytoplasmic 
side, or inside-out signaling (Ginsberg et al., 1992, Rojiani 
et al., 1991). Engagement of ad, even in a similar cellular 
context as other leukointegrins, may involve interactions 
with a distinct subset of cytosolic proteins and may have 
functional consequences specific to ad. 
Cotransfection of the cDNAs encoding ad and CD16 
into CHO cells resulted in cell surface expression of a 
heterodimeric molecule, both chains of which were immu- 
noprecipitated by either anti-CD16 or anti-ad MAb (Fig- 
ure 2). 
The ad-specific MAb used in this experiment was gener- 
ated from mice injected with CD16 complexes isolated 
from human splenic lysates precleared of CD1 la and 
CD1 1 b. Supernatants from resulting immunoglobulin G 
(IgG)-secreting hybridomas were screened by flow cytom- 
etry for reactivity with ad/CD1 6 CHO transfectants but not 
with JY cells, which had been previously determined by 
Northern blot analysis to be ad negative. The IgGl anti- 
body secreted by clone 169A was determined to be specifi- 
cally reactive with ad only by flow cytometric analysis of 
stablead/CDl6,CDlla/CD16,CDllb/CD16,andCDllc/ 
CD1 6 CHO transfectants (Table 1, stable transfectants). 
This antibody was not observed to have inhibitory activity 
in the functional assays presented here. 
To ascertain cell-type expression of ad and its relation- 
ship to expression of other leukointegrins, the presence 
of ad protein on human lymphoid and myelomonocytic cell 
lines and on freshly isolated peripheral blood leukocytes 
(PBLs) was evaluated by flow cytometry using the MAb 
169A and compared with expression of CD1 la, CD1 1 b, 
and CDllc (Table 1). ad expression is modulated with 
differentiation of the myeloid cell lines HL60 and THP-1 
(Table 1, cell lines). DMSO treatment, which induces gran- 
ulocyte differentiation in the promyelomonocytic line HL60 
(Collins, 1967) did not affect the percent of cells positive 
for ad, which was expressed on more cells than CD1 lc 
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both before and after treatment. However, phorbol myris- 
tate acetate (PMA) stimulation of both HL6Cl and THP-1 
cells along a macrophage-like differentiation pathway re- 
sulted in increased CD1 1 b and CD1 lc expression levels, 
with a corresponding reduction in percent positive for ad. 
The majority of peripheral blood lymphocytes express low 
levels of ad relative to CD1 1 a and CD1 1 b (Table 1, PBL); 
these patterns do not vary significantly among donors. 
Granulocytes were also observed to express ad, although 
at significantly lower levels than CD1 1 b. Expression ap- 
peared to increase rapidly on granulocytes with PMA or 
f-Met Leu-Phe (fMLP) stimulation, consistent with recruit- 
ment of an intracellular pool of ad in these cells. Thus, 
levels of ad expression may differ from that of CDlla, 
CD1 1 b, or CD1 lc depending on the cell type and activa- 
tion or differentiation state. 
Comparative expression of the previously identified leu- 
kointegrin a chains and ad was assessed by immunohis- 
tology in the spleen because of the highly ordered struc- 
ture of the lymphoid domains and the presence of diverse 
cell types. The overall pattern of ad distribution in the red 
pulp of spleen was overlapping with but not identical to 
that of CDlla, CD1 lb, and CDllc (Figure 3). Whereas 
CD1 1 a was diff usely expressed by leukocytes in all splenic 
domains, including lymphoid domains of the white pulp 
and marginal zone and cords and sinuses of the red pulp, 
CD1 1 b, CD1 lc, and ad expression patterns were more 
restricted. CD1 1 bstaining was prominent on granulocytes 
in the red pulp cords and sinuses. CD1 lc was expressed 
by dendritic cells in the periarterial lymphoid sheaths, mar- 
ginal zones, and follicles of the white pulp. The distribution 
of ad was predominantly localized to the red pulp cords 
and sinuses on small and large mononuclear cells and 
granulocytes. Expression of ad in the white pulp was lim- 
ited to scattered dendritic cells occurring less frequently 
than CD1 lc+ cells. Although relative intensity of splenic 
integrin staining appeared to vary among three tissue do- 
nors (data not shown), probably owing to differences in 
age, health, or mortality factors, the distribution patterns 
did not vary. 
A preliminary evaluation of ad expression in pathologic 
tissue with macrophage-specific etiology was performed 
using sections of abdominal aorta selected for the inci- 
dence of fatty streaks, which histologically consisted of 
subintimal infiltrates of smaller leukocytes and aggregates 
of foamy macrophages (Pathobiological Determinants of 
Atherosclerosis in Youth [PDAY] Research Group). These 
highly specialized macrophages are implicated in the es- 
tablishment of subintimal aortic fatty streaks, which may 
progress to fulminant atherosclerotic lesions (Ross, 1993). 
Foamy macrophages can be identified in fatty streaks by 
detection of ingested lipid with the Oil Red 0 stain and 
differentiated from lipid-containing smooth muscle cells 
by specific markers. In the Oil Red O-positive sections 
we examined, a subset of the large lipid-laden cells reac- 
tive with an antibody to CD68, a macrophage-specific 
marker, expressed moderate levelsof ad (Figure 3). These 
cells were not stained by an antibody to smooth muscle 
actin, confirming that the ad+ foam cells were not of 
smooth muscle origin (data not shown). In addition, these 
macrophage-like cells did not stain with CD3, CD& or 
CD20 antibodies (data not shown). Double-labeled aortic 
sections confirm a significant overlap of CD68 and ad 
staining. The ad-specific antibody did not react with aottic 
sections that were Oil Red 0 negative (data not shown). 
Typically, the leukocyte integrins promote cell-cell con- 
tact by binding to the intercellular adhesion molecules 
(ICAMs) (Hynes, 1992; Larson and Springer, 1990). Solu- 
ble forms of ICAM- and ICAM- have been observed in 
serum with increased levels in certain pathologic condi- 
tions (Martin et al., 1995). Therefore, the ability of CHO 
cells expressing ad/CD16 or LFA-1 to bind soluble 
ICAM-3/lg, ICAM-l/IQ, and VCAM-1119 chimeric proteins 
was assessed by flow cytometry (Figure 4A). The ad/ 
CD1 8, LFA-1, and VLA-4 transfectants used in subsequent 
binding experiments were 60%-90% CD18 or a4 positive, 
with equivalent cell surface expression in individual experi- 
ments. In replicate experiments, ICAM-3/lg, but not 
ICAM-l/IQ or VCAM-l/IQ, bound to ad/CD18 transfectants. 
The CD18 dependence of this binding was confirmed by 
its sensitivity to treatment with anti-CD1 8 antibody. Similar 
results were obtained for ad/CD18 cotransfectants in ad- 
hesion assays using immobilized ICAM-lllg or ICAM-3/lg 
chimeras (Figure 48). The ad/CD18 transfectants bound 
2- to 4-fold greater to ICAM-3/lg than to the bovine serum 
albumin (BSA) control, with no significant binding to 
ICAM-l/IQ. 
Treatment of ad/CD18 transfectants with PMA or man- 
ganese, positive regulators of LFA-1 activation, did not 
significantly affect binding to CAMS in either of the adhe- 
sion assays described. CD1 la/CD18 transfectants exhib- 
ited a PMA-dependent 3- to 5-fold increase in binding to 
ICAM- (Figure 48) consistent with the activation require- 
ment and apparent avidity reported for LFA-l/ICAM-1 in- 
teractions in this cellular context (Dustin and Springer, 
1989;van Kooyketal., 1989). Differences inadandCD1 la 
regulation may reflect unique cytosolic interactions medi- 
ated by their nonhomologous cytoplasmic tails. 
In summary, we have described a previously unknown 
human leukointegrin a subunit that forms a functional het- 
erodimer with CD18. Although structurally similar to the 
known a chains, divergence in key regions of this protein 
implies that ad/CD18 plays a different role in immune re- 
sponses. For example, the distinct sequences of the ad 
I domain and cytoplasmic tail region suggest the potential 
for unique ligands, or unique binding sites on shared li- 
gands, and affinity regulation specific to this integrin. 
The predominant expression of ad observed on special- 
ized cells in tissues suggests that the major functions of 
ad may be restricted to particular microenvironments. For 
example, the presence of ad on splenic red pulp macro- 
phages may indicate a role for this integrin in phagocytosis 
of effete erythrocytes, bloodborne pathogens, and particu- 
late matter from the blood. The involvement of foam cells 
in establishment of vascular lesions in certain types of 
atherosclerosis (Ross, 1993), combined with the obsetva- 
tion that ad is expressed on those cells in fatty streaks, 
suggest that ad may contribute to macrophagespecific 
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Figure 3. Expression of ad in Human Spleen and Aorta 
(A) Fresh frozen splenic sections were acetone fixed and treated with antibodies against (1) ad, (2) CD1 la, (3) CD1 1 b, (4) CD1 lc, or (5) irrelevant 
mouse IgGl. 
(6) Abdominal aortic sections were acetone fixed and treated with (1) Oil Red 0, (2) MAb 169A (ad) (blue), (3) MAb EBMll (CD66) (blue), (4) both 
169A (blue) and EBMll (brown), and (5) irrelevant mouse IgGl 
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activities such as phagocytosis of modified lipoproteins in 
these lesions. Therefore, animal models of atherosclero- 
sis may present one interesting venue to explore the in 
vivo function of ad. 
The relevance of the low levels of ad observed on granu- 
locytes, peripheral blood T cells, and monocytes may be- 
come evident when the full range of ad functions is 
defined. The presence of ad protein in CD18 immunopre- 
cipitations from PBL may easily have been overlooked in 
the past due to overwhelming levelsof other leukointegrins 
and similarity in apparent molecular weights of the a 
chains. It is possible that ligand specificity, activation regu- 
lation, and increased expression levels in particular envi- 
ronments may confer to ad different functions than other 
leukointegrins expressed by these cells. 
The cell type and tissue distribution of human and ca- 
nine ad protein expression is only partially conserved. As 
in the dog, ad is expressed on splenic red pulp macro- 
phages (Danilenko et al., 1995) but not on Kupffer cells, 
resident macrophages of the liver (data not illustrated). 
However, the presence of ad on peripheral blood and 
splenic granulocytes from humans contrasts with the dog. 
This cross-species variation is perhaps unsurprising con- 
sidering the presence of CD4 on canine, but not human 
granulocytes (Moore, et al., 1992). Other tissues that differ 
in ad distribution or intensity or both between the human 
and other species may be attributed either to species dif- 
ferences or to the variable characteristics of human donor 
tissues. 
The capacity of ad/CD18 to bind both soluble and immo- 
bilized ICAM- implies a higher affinity interaction than 
that observed for LFA-1, which does not bind ICAM- in 
Figure 4. ad/CD18 Binds to Soluble and Immobilized lCAM-3 
The ability of stable ad/CD18 CHO transfectants to recognize soluble 
(4A) and immobilized (48) ICAMS and ICAM- was determined. 
(A) Transfectants were incubated in buffer with ICAkKWg, ICAM-I/ 
lg, or VCAM-1110. Bound protein was detected with FITC-conjugated 
anti-human immunoglobulin and subsequent flow cytometric analysis. 
(1) Comparison of ICAM-3Ag and VCAM-lllg binding; (2) relative bind- 
ing of ICAM3/lg in the presence or absence of manganese; (3) inhibi- 
tion of ICAM-3Ilg binding by TS1118 relative to VCAM-1119 binding; 
(4) comparison of ICAM-lllg and VCAM-1IIg binding; (5) VCAM-l/Ig 
binding to transfectants relative to anti-human immunoglobulin tracer 
antibody only; (6) surfaceCD18expression on adKD18CHO transfec- 
tants, detected with the anti-CD18 MAb TS1118; (7) a4 expression on 
VIA-4 CHO transfectants, detected with the antibody A4.1; and (8) 
binding of VCAM-1110 and ICAMBllg to VLA-4 CHO transfectants. 
Mock-transfected and untransfected cells were not recognized by any 
fusion protein or by the FlTC-conjugated tracer antibody (data not 
shown). 
(6) CHO transfectants labeled intracellularly with calcein were incu- 
bated on microtiter platescoated with ICAM-3/lgor ICAM-lllg. Fluores- 
cence before and after washing was determined. Data is presented 
as fold increase of binding to ICAMllg over BSA control. Maximal 
binding of ad/CD18 CHO to lCAM-3 was 30%-50% of cells added to 
plates; for LFA-1 (PMA+) and ICAM-1, 20%-30%; and 5%-10% for 
all transfectants to BSA. (1) Binding of CHO transfectants to ICAM-3/ 
lg; (2) binding of CHO transfectants to ICAM-l/Ig. The CDlWCD18 
transfectants did not show significant binding to ICAM-3, perhaps ow- 
ing to modest surface expression of LFA-1. No binding of ad/CD18 
or CD1 la/CD18 transfectants to VCAM-IIIg was observed (data not 
shown). 
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a similar cellular context. In addition, the failure of ad/ 
CD18 to bind soluble or immobilized ICAM- or VCAM-1 
suggests an exclusive ICAM- recognition by this integrin. 
However, the ad subunit, like other leukointegrin a chains, 
probably recognizes multiple ligands and may exhibit addi- 
tional CAM binding specificities when expressed in other 
cellular contexts in vivo. We are currently attempting to 
define the unique functional range of the ad molecule. 
Moreover, reevaluation of many leukointegrindependent 
immune phenomena may now be warranted to determine 
the contribution of this previously unrecognized family 
member. 
Experimental Procedures 
Isolation of the ad cDNA 
ad/CD16 complexes affinity purified from detergent lysates of canine 
spleen (Danilenko et al., 1992) were subjected to preparative SDS- 
PAGE in 7% polyacrylamide and transferred to PVDF membranes. 
The Coomassie-stained 150 kDa band was fragmented with cyanogen 
bromide (CNBr) in 70% formic acid. CNBr-cleaved protein was eluted 
once with 60% acetonitrile, 0.1% TFA. and once with 60% acetonitrile, 
0.06% TFA. The CNBr fragments were dried by vacuum, reduced and 
alkylated. and digested with trypsin (Stone et al., 1992). Resulting 
peptides were separated on a Waters Associates high pressure liquid 
chromatography system using a Vydac C-16 column and sequenced 
by Edman degradation. 
Degenerate oligonucleotides were designed on the peptide se- 
quences (FNLDVEEPMVFQED) and (FQEGFSSVLT). Double- 
stranded cDNA was generated from canine splenic poly (A)+ mRNA 
(Gubler and Hoffman, 1963). A PCR containing the oligonucleotides 
(RAANCCYTCYTGRAAACTYTC) and (TTYAAYMNGAYGTNGARG- 
ARCC) and 200 ng cDNAyielded a 1 kb product, which was ligated into 
the pCRll vector (Invitrogen, San Diego, California) and sequenced by 
the Sanger dideoxy termination method. 
Oligo dT-primed double-stranded cDNA was prepared from poly(A)+ 
RNA isolated from normal human spleen. B&Xl linkers were added 
to the cDNA prior to cloning into pCDNA.Amp (Invitrogen). The 
%P-labeled canine ad fragment was added to colony replicas in prehy- 
bridization buffer (5x SSC, 10x Denhardt’s, 1% SDS, 30% for- 
mamide), and allowed to hybridize overnight at 42’C. The final strin- 
gency wash was at 65°C in 1 x SSC, 0.1% SDS. A single clone, 
1 QA2. was identified and sequenced on the sense strand by the nested 
deletions technique. The antisense strand was sequenced for confir- 
mation. 
Expression and Analysis of the ad cDNA 
An oligonucleotide was designed to include a 5’ EcoRl site, modified 
Kozak consensus sequence (Korak, 1967) an adenosine, and se- 
quence overlapping the 5’ end of clone 1 QA2 (AGTTACGAATTCGC- 
CACCATGACCTTC GGCACTGTG), A 796 bp fragment was amplified 
from clone 19A2 using this oligo and a specific internal oligonucleotide 
from the antisense strand (CCACTGTCAGGATGCCCGTG). The PCR 
product was restricted with EcoRl and BamHl and ligated to the 3.2 kb 
BamHI-Xbal fragment from 19A2. The resulting EcoRI-Xbal fragment 
was ligated into pcDNA3 (Invitrogen) resulting in the plasmid 
pATM.Di2. The cDNAs encoding human CDlla, CD16. and CD29 
(51) were each subcloned into the expression vector pDC1. A pCDM6 
construct containing the CD1 lc cDNA was obtained from F. Sanchez- 
Madrid (Universidad Autonoma de Madrid, Spain). The CD49d (a4) 
and CD1 1 b encoding cDNAs were subcloned into the pcDNA.1 vector 
(Invitrogen). The plasmids pATM.DlP and pDCl.CD16 were used to 
transfect DHFR-DG44. CHO cells (obtained from L. Chasen, Colum- 
bia University, New York) by electroporation. The plasmid 
pDC1 .CDl la was transfected along with pDC1 .CD16 as a positive 
control. Vectors expressing a4 and 61 were cotransfected to provide 
a positive control for VCAM-1 binding experiments. Stably transfected 
clones were selected in nucleoside-deficient medium. 
Eiotinylated (Cole et al., 1967) CD16 complexes were precipitated 
from detergent lysates of CHO transfectants with the monoclonal anti- 
body TS1116 (American Type Culture Collection ]ATCC] HB203) or 
169A(anti-ad). Biotinylated protein was isolated under reducing condi- 
tions on 6% polyacrylamide gets and transferred to PVDF membranes. 
Biotinylated proteins were detected with Strepavidin POD (Boehringer 
Mannheim) diluted I:6000 in TBS-T, 0.3% BSA. Hyperfilm (Amer- 
sham) was used to expose the membranes for OS-2 min after develop 
ment with enhanced chemiluminescence reagents (Amersham). 
Generatlon of ad-Speclflc MAbs 
Detergent lysates were made as previously described (Danilenko et 
al., 1992) from 100 g of human spleen obtained from the University 
of Utah. Lysates were clarified by centrifugation and sequentially pre- 
cleared of LFA-1 and Mac-l with Affigel 10 resin to which the antibody 
TS1/22.1 (ATCC HB202) or 44aacb (ATCC HB249) was bound. Re- 
maining CD16 complexes were affinity purified with the murine anti- 
body TSlH6. BALBlc mice were immunized three times at 21 day 
intervals with 30 ug/mouse protein in adjuvant. The spleen from a 
single mouse was fused with NS-1 myeloma cells and hybridomas 
were obtained according to standard procedures. Culture superna- 
tants were analyzed by flow cytometry for the ability to react with ad/ 
CD16 CHO ceils but not with JY cells, which in our hands express only 
CD1 la/CDlB. The clone 169A (IgGl) was isolated after two rounds of 
subcloning. Antibody purified from exhausted hybridoma supernatant 
on a PROSEP-Acolumn (Bioprocessing Limited) according to package 
directions was used in the flow cytometric experiments presented; 
histologic analysis was performed using supernatants. 
Flow Cytometric Analysls of ad Expresaion 
Surface expression of leukointegrin a chains on cell lines, PBLs, and 
transfectants was detected with the murine MAbs 169A (ad), TS1122 
(CD1 la, ATCC), 44aacb (CD1 lb, ATCC), and BU15 (CD1 lc, Dako). 
Human PBLs were isolated from blood on a Histopaque 1077 (Sigma) 
gradient using standard procedures. Granulocytes were isolated on 
Ficoll-Hypaque gradients (Ferrante and Thong, 1982). Cellular Fc 
were blocked with 1 mglml human IgG (Sigma) in RPM with 2% fetal 
bovine serum and 0.01% sodium azide (FACS buffer) for 30 min on 
ice. Cells (IO? per group were incubated on ice in 100 pl FACS buffer 
with primary antibody at 10 Pa/ml or 100 ul hybridoma supernatant. 
Bound antibody was detected with sheep anti-mouse IgG-fluorescein 
isothiocyanate (FITC) (Sigma), followed by washing and analysis on 
a Becton-Dickinson FACscan using Lysis II software. 
lmmunohlstology 
Frozen sections from human abdominal aorta (PDAY Research 
Group) were stained with irrelevant murine IgG or MAb 169A (ad). 
Bound antibody was detected using rabbit anti-mouse IgG (Dako) and 
mouse APAAP reagent (Dako) with subsequent development with Sub- 
strate Kit Ill (Vector). Sections were counterstained with Nuclear Fast 
Red (Vector). Human spleen and liver sections (National Disease Re- 
search Interchange) were treated in the same fashion, but with the 
addition of MAbs against CDlla (TS1/22, ATCC), CD1 lb (44aacb, 
ATCC), and CD1 1 c (BU15, Dako). Aortic sections stained with Oil Red 
0 were dehydrated with 100% propylene glycol before staining. For 
double staining, MAb EBMll (CD66)-treated sections were incubated 
successively with supersaturating concentrations of peroxidase- 
conjugated anti-mouse IgG (1 :lOO, Dako) and peroxidaseconjugated 
swine anti-rabbit IgG (130, Dako). Sections were blocked with swine 
anti-rabbit IgG before addition of MAb 169A. Slides were developed 
with the DAB (3.3 diaminobenzidine) kit (Vector) and the AP (alkaline 
phosphatase) Substrate Ill kit (Vector). 
CAM Binding Assays 
To analyze ad/CD16-CAM interactions in solution, lO”(per group) ad/ 
CD16 CHO transfectants from suspension cultures were incubated 
for 20 min at room temperature in 100 ul buffer only (Tris-buffered 
saline, 0.1% BSA), buffer with 10 ug/ml MAb, or buffer with 2 mM 
MgCI,. After washing, cells were incubated in buffer only or buffer ( f 
MgCIS with 10 pglml ICAM-3/lg, ICAM-l/IS, or VCAM-1110 (Sadhu et 
al., 1994) for 30 min at room temperature. Bound fusion protein was 
detected with goat anti-human IgG-FITC (Jackson Labs, West Grove, 
Pennsylvania) diluted 1 :lOO in buffer, followed by washing and subse- 
quent analysis on a Becton-Dickinson FACscan. 
For analysis of integrin binding to immobilized CAM/IS, microtiter 
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plates were coated with 10 pg/ml soluble ICAM-3/lg or ICAM-l/Ig, or 
1% BSA and blocked with 1% BSA. CHO transfectants (1 x 10’) per 
group were labeled with 6 pg calcein dye (Molecular Probes, Eugene, 
Oregon) in phosphate-buffered saline. Calcein-labeled cells were 
washed and resuspended in buffer with or without 10 pa/ml TS1116 
and incubated at 37OC for 25 min in triplicate wells/group on microtiter 
plates. After washing by immersion in phosphate-buffered saline with 
0.1% BSA for 20 min, remaining fluorescence was determined with 
an automatic fluorescence reader (Cyto Fluor 2300-2350, Millipore). 
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